Core Viewpoint - MicroPort CardioFlow-B (02160) has announced significant growth in its VitaFow® transcatheter aortic valve and delivery system, with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The company expects the implantation volume to exceed 850 cases in 2025, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is projected to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® in European countries following CE certification and increased market share in emerging markets in Asia and Latin America [1] Group 2: Strategic Development - The board believes that the recent acquisition of MicroPort Cardiac Rhythm Management will enhance local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advancing the research and clinical progress of next-generation TAVI products, and enhancing its comprehensive competitiveness in the global valve treatment field [1]
微创心通-B(02160)：VitaFow®系列经导管主动脉瓣膜及输送系统已进入全球35个国家及地区 累计植入量近1300例